Cabometyx优于Stivarga作为二线肝癌治疗

StephenW

Cabometyx superior to Stivarga as second-line liver cancer treatment
September 24, 2019

Treatment with Cabometyx as second-line therapy for patients with advanced hepatocellular carcinoma who previously received Nexavar demonstrated superior progression-free and overall survival compared with Stivarga, according to a study presented at the International Liver Cancer Association 2019 meeting and a press release.

“Hepatocellular carcinoma is a devastating disease with only a few treatment options demonstrating survival benefits and many investigational drugs have failed to meet overall survival endpoints in clinical trials,” Katie Kelley, MD, study investigator from the University of California, San Francisco, said in the release. “[This] analysis brings further insight into the comparative effectiveness of the key second-line treatments for advanced hepatocellular carcinoma, particularly in relation to important endpoints like progression-free survival. These results may support clinicians in making informed treatment decisions in order to deliver optimal care for their patients.”

Kelly presented results from a matching-adjusted indirect comparison (MAIC) of Cabometyx (cabozantinib, Ipsen) vs. Stivarga (regorafenib, Bayer) for the second-line treatment after Nexavar (sorafenib, Bayer). Investigators used data from the phase 3 CELESTIAL and RESOURCE trials for the comparison.

In the CELESTIAL trial, cabozantinib improved median progression-free survival (5.2 vs. 1.9 months; 95% CI, 4-5.5) and median overall survival (10.2 vs. 8 months; 95% CI, 9.1-12) compared with placebo.

The comparison study matched patients by baseline characteristics including age, race, geographical region, Eastern Cooperative Oncology Group performance status, Child-Pugh class, duration of prior sorafenib treatment, extrahepatic disease, macrovascular invasion, etiology of HCC, and alpha-fetoprotein tumor marker levels. Results showed that cabozantinib improved progression-free survival (5.6 vs. 3.2 months; 95% CI, 4.9-7.26) and numerically improved median overall survival (11.4 vs. 10.8 months) compared with regorafenib.

“At Ipsen, our mission is to prolong and improve patients’ lives and health outcomes, and we acknowledge the importance of providing health care professionals with the best available evidence to achieve these goals for patients,” Yan Moore, MD, senior vice president and head of oncology therapeutic area at Ipsen, said in the release. “While alternative methodological approaches such as MAIC are not substitutes to evidence-based prospective clinical trials, it is important to recognize the need for further insights into the comparative effectiveness of current treatment approaches.” – by Talitha Bennett

Reference: www.ipsen.com

StephenW

Cabometyx优于Stivarga作为二线肝癌治疗
九月24，2019

根据国际肝癌协会2019年会议和新闻发布会上的一项研究，与之前的Stivarga相比，使用Cabometyx作为二线治疗的先前接受Nexavar治疗的晚期肝细胞癌的患者无进展和总体生存率更高。

加州大学旧金山分校的研究人员凯蒂·凯利（Katie Kelley）博士说：“肝细胞癌是一种毁灭性疾病，只有少数几种治疗方法显示了生存益处，而且许多研究药物未能达到临床试验中的总体生存终点。”发布。 “ [此]分析为晚期肝细胞癌的关键二线治疗的相对有效性，尤其是与诸如无进展生存期等重要终点的比较，带来了进一步的洞察力。这些结果可能支持临床医生做出明智的治疗决策，以便提供为患者提供最佳护理。”

凯利（Kelly）提出了奈贝（Nexavar）（索拉非尼（Sorafenib），拜耳（Bayer））进行二线治疗时，卡博美斯（cabozantinib，Ipsen）与斯蒂伐加（regorafenib，Bayer）的匹配调整间接比较（MAIC）。研究人员使用了3期CELESTIAL和RESOURCE试验的数据进行比较。

在CELESTIAL试验中，与安慰剂相比，卡波替尼改善了无进展生存期的中位值（5.2 vs. 1.9个月； 95％CI，4-5.5）和中位总体生存期（10.2 vs. 8个月； 95％CI，9.1-12）。

对比研究通过基线特征匹配患者，包括年龄，种族地区，东部合作肿瘤小组的表现状态，Child-Pugh等级，索拉非尼先前治疗的持续时间，肝外疾病，大血管浸润，HCC病因和甲胎蛋白肿瘤标记物水平。结果显示，与雷戈非尼相比，卡巴替尼改善了无进展生存期（5.6 vs. 3.2个月； 95％CI，4.9-7.26），并在数值上改善了中位总体生存期（11.4 vs. 10.8个月）。

“在益普森，我们的任务是延长和改善患者的生命和健康状况，我们认识到为医疗保健专业人员提供最佳可用证据以实现患者目标的重要性，”医学部高级副总裁Yan Moore博士““虽然诸如MAIC之类的替代方法学方法不能替代基于证据的前瞻性临床试验，但重要的是认识到需要进一步洞察当前治疗方法的相对有效性。” – Talitha Bennett

参考：www.ipsen.com

挚友888888

THANKS